More on Halozyme Therapeutics (NASDAQ:HALO): Q1 comes in mixed, beating on its top line but...

More on Halozyme Therapeutics (NASDAQ:HALO): Q1 comes in mixed, beating on its top line but coming up short on a per share basis. Total sales climbed by nearly 60% Y/Y, driven by R&D reimbursements from partners primarily related to manufacturing activities to support potential launches. R&D expenses related to those activities also rose however, which, along with an increase in clinical trial activities, contributed to the bottom line shortfall.